What are the side effects of Ruxolitinib?

In a double-blind, randomized, placebo-controlled study of Ruxolitinib tablets, among 155 patients with myelofibrosis treated, the most common adverse reactions were thrombocytopenia and anemia. Thrombocytopenia, anemia, and neutropenia were dose-related effects. The three most common non-hematological adverse reactions were bruising, dizziness, and headache. Post-marketing adverse events of herpes simplex virus reactivation and/or transmission.

The most common side effects of ruxolitinib in polycythemia vera include thrombocytopenia, anemia, weight gain, headache, dizziness, hypercholesterolemia, and elevated liver enzyme levels. In acute graft-versus-host disease, common side effects include thrombocytopenia, anemia, neutropenia, cytomegalovirus infection, sepsis (when bacteria and their toxins circulate in the blood causing organ damage), urinary tract (the structure that carries urine) infection, hypercholesterolemia, and elevated liver enzyme levels. In chronic graft-versus-host disease, common side effects include thrombocytopenia, anemia, neutropenia, hypertension, headache, urinary tract infection, hypercholesterolemia, and elevated liver enzyme levels.

Ruxolitinib tabletsThe original drug has been launched in China and is included in the scope of Class B medical insurance. It is limited to patients who meet the indications. Specification The price of each box of 5mg*60 tablets may be around RMB 3,000. The Turkish version of ruxolitinib tablets listed overseas, Specifications20mg*56 tablets, may be priced around RMB 8,000 per box (the price may fluctuate due to exchange rates). There are also ruxolitinib tablets produced in other countries. For example, the price of 5mg*50 tablets produced by Bangladesh Yaopin International may be around 1,400 yuan per box (the price may fluctuate due to exchange rates). Its pharmaceutical ingredients are basically the same as those of domestic and foreign original drugs.